Biomanufacturing

Defining and Describing Biomanufacturing

Biomanufacturing uses living cells, enzymes, or whole biological systems—often genetically engineered—to make products at industrial scale that would be hard or impossible to produce by conventional chemistry alone. [z4rs6j] [zmq1dm] [sacri9] [lpky89]
In policy and technical literature, biomanufacturing is typically defined as the use of engineered or non‑native biological systems to produce materials, chemicals, and medicines, applying principles of engineering, chemistry, and biotechnology. [z4rs6j] [8xlze4] [iw6fgp] [lpky89] It usually refers to the manufacturing or commercial production stage, distinguishing it from earlier bioprocess development or lab‑scale research. [zmq1dm] [v2e9o5] [sacri9] The term matters because it sits at the intersection of industrial production, synthetic biology, and regulation, and is now central to debates about industrial strategy, green transitions, and advanced medicine production in the US, EU, and elsewhere. [8xlze4] [iw6fgp] [sacri9] [lpky89]
flowchart LR A["Engineered cells or enzymes"] B["Upstream processing"] C["Bioreactor production"] D["Downstream purification"] E["Formulation and fill finish"] F["Finished bioproduct"] A --> B B --> C C --> D D --> E E --> F
A commonly cited formulation from the US CDC states that “Biomanufacturing is the use of biological systems that have been engineered, or that are used outside their natural context, to produce a product.” [z4rs6j] EuropaBio and other European industry groups similarly emphasize industrial production using biotechnology, positioning biomanufacturing as a key enabler of the EU’s “green and digital transitions.” [8xlze4] [iw6fgp] In biopharmaceutical contexts, specialized sources distinguish bioprocessing (development and optimization) from biomanufacturing (GMP‑regulated, large‑scale production and commercialization) of biologic drugs. [zmq1dm] [v2e9o5] [sacri9]
Biomanufacturing can involve:
  • Living cells (e.g., microbial, plant, or mammalian cell cultures in bioreactors) that produce proteins, vaccines, or materials. [zmq1dm] [3ijjtn] [sacri9]
  • Cell‑free systems or enzymes used outside their native context to catalyze specific reactions. [z4rs6j] [lpky89]
  • Integrated digital and automation layers such as “digital twins in a biomanufacturing environment” to model and control processes across the drug product lifecycle. [v2e9o5] [sacri9]
Across these variants, the shared idea is industrial‑scale, often GMP‑compliant, production of high‑value products by leveraging designed biological systems rather than purely chemical synthesis. [z4rs6j] [zmq1dm] [v2e9o5] [sacri9] [lpky89]

Uses in Context

  • In biopharmaceutical production, the term is used to describe the industrial, regulated stage of biologics manufacturing: “Biomanufacturing focuses on the large‑scale production of biologics under strict GMP‑regulated environments,” including “industrial‑scale manufacturing, validation, quality assurance, and the infrastructure required to bring biologic therapies from development into commercial production.” [zmq1dm]
  • In occupational safety and health, NIOSH frames biomanufacturing as both an opportunity and a risk area: advances in biomanufacturing bring “both opportunities to society, but also the potential for worker exposure,” and NIOSH studies hazards as these technologies “move from small laboratories to large manufacturing platforms.” [z4rs6j]
  • In industrial and economic policy, European industry associations invoke “biomanufacturing” when arguing for supportive regulations; a Cefic position paper calls for “establishing uniform definitions for biotechnology and biomanufacturing” and using policy tools such as “regulatory sandboxes” and funding to support industrialization. [iw6fgp]
  • In EU bioeconomy and industrial strategy debates, EuropaBio’s Biomanufacturing Platform states its mission is “to represent biomanufacturing at the highest policy levels in Europe, to ensure that it is recognised within the EU Industrial Strategy and highlight its key contribution to Europe’s industrial transformation through the twin, green and digital transitions.” [8xlze4]
  • In semantic and conceptual analysis of biotechnology, scholars note that “more recent terms such as biomanufacturing, synthetic biology and engineering biology also lack consensual definitions despite their use in both policy and scientific domains,” and propose clarifying how these terms are used in funding and regulatory contexts. [lpky89]
  • In advanced manufacturing of medicines, engineering and medical communities speak of “advanced biomanufacturing for medicines” to capture cutting‑edge methods for producing therapeutic proteins, cell therapies, and other complex biologics at scale, emphasizing rapid innovation in “advanced biomanufacturing” of drugs. [sacri9]

History of Use

Origins

  • Academic and policy analyses note that biomanufacturing emerged as a term alongside modern biotechnology and synthetic biology but “lacks a consensual definition” despite its growing presence in funding calls and strategies. [lpky89] The Wageningen University analysis “Addressing semantic ambiguity in biotechnology” explicitly groups “biomanufacturing, synthetic biology and engineering biology” as newer terms needing clearer conceptual boundaries. [lpky89]
  • Early technical uses in engineering and bioprocess literature framed biomanufacturing as the industrial application of bioprocesses and bioreactors to produce pharmaceuticals and bio‑based materials, building on decades of biochemical engineering work but distinguishing the high‑volume, regulated manufacturing stage from lab‑scale biotechnology. [zmq1dm] [sacri9] [lpky89]
  • In US government and occupational‑health contexts, NIOSH and related agencies adopted the term as they began to address safety in “biomanufacturing and synthetic biology,” defining it operationally as engineered biological systems used “outside their natural context” for product manufacture. [z4rs6j]

Evolution

  • 2000s–early 2010s – From biotechnology to biomanufacturing. As biopharmaceuticals and industrial biotechnology matured, practitioners increasingly contrasted bioprocess development with biomanufacturing, reserving the latter for full‑scale GMP production and commercialization of biologics. [zmq1dm] [sacri9] [lpky89] This period saw the term used to highlight manufacturing scale‑up challenges distinct from upstream research.
  • Mid‑2010s – Integration with synthetic and engineering biology. With the rise of synthetic biology and “engineering biology,” biomanufacturing began to be framed as the downstream realization of design‑build‑test‑learn cycles, using engineered organisms as programmable factories. [3ijjtn] [sacri9] [lpky89] Research initiatives in areas like PHA (polyhydroxyalkanoate) biosynthesis explicitly used “bio‑manufacturing” to describe efforts to “accelerate the design‑build‑test‑learn (DBTL) cycle” for sustainable bioproducts. [3ijjtn]
  • Late 2010s–2020s – Policy and industrial strategy term. In Europe and other regions, biomanufacturing became a key term in industrial policy, with platforms such as EuropaBio’s Biomanufacturing Platform created “to represent biomanufacturing at the highest policy levels in Europe” and embed it within the EU Industrial Strategy and “twin, green and digital transitions.” [8xlze4] [iw6fgp] [lpky89] Position papers from Cefic and others call for uniform definitions and regulatory frameworks specifically addressing biomanufacturing. [iw6fgp]
  • 2020s – Digital and “advanced biomanufacturing” for medicines. New work on “advanced biomanufacturing for medicines” and on “digital twins in a biomanufacturing environment” reflects an evolution from purely biological to cyber‑physical systems, using modeling, analytics, and automation across the drug product lifecycle. [v2e9o5] [sacri9] Biomanufacturing in this sense now encompasses both the biological production platform and the digital layer used to design, monitor, and optimize it. [v2e9o5] [sacri9]

Best Real-World Examples

  • BioPhorum biomanufacturing digital twins initiative – An industry consortium effort that “defines digital twins for biomanufacturing,” offering a consensus framework for implementing models that mirror bioprocesses and facilities across the drug product lifecycle. [v2e9o5]
  • Global Center for Sustainable Bioproducts – Bio‑manufacturing research – An academic center focusing on bio‑manufacturing of polyhydroxyalkanoates (PHAs), aiming “to accelerate the design-build-test-learn (DBTL) cycle of PHA biosynthesis” for sustainable materials production. [3ijjtn]
  • EuropaBio Biomanufacturing Platform – A European industry platform created “to represent biomanufacturing at the highest policy levels in Europe” and to integrate biomanufacturing into EU industrial and green‑transition strategies. [8xlze4]
  • NIOSH Biomanufacturing and Synthetic Biology program – A US occupational‑health program that studies hazards and develops guidance as biomanufacturing moves “from small laboratories to large manufacturing platforms,” focusing on worker safety in facilities using engineered biological systems. [z4rs6j]
  • Bioprocessing vs Biomanufacturing analysis (Conferenzia World) – An industry explainer widely used in conferences and training that clarifies how “bioprocessing refers to the development and optimization” of biological systems, whereas “biomanufacturing focuses on the large-scale production of biologics” under GMP, helping organizations structure roles and investments. [zmq1dm]
  • The Bridge – “Advanced Biomanufacturing for Medicines” issue – A themed issue of the US National Academy of Engineering’s magazine presenting “cutting-edge perspectives on the rapid progress and innovation in advanced biomanufacturing for medicines,” from continuous manufacturing to novel modalities. [sacri9]
  • Semantic analysis of biomanufacturing and related terms – A research effort that uses funding proposals and policy documents to show how “biomanufacturing, synthetic biology and engineering biology” are used ambiguously, illustrating the concept’s contested and evolving boundaries. [lpky89]

Case Studies

1. Digital Twins for Biomanufacturing in Biopharmaceutical Plants

BioPhorum, a collaboration forum for biopharmaceutical manufacturers and suppliers, convened industry experts to define what a digital twin means specifically “in a biomanufacturing environment,” recognizing that inconsistent usage was hindering deployment. [v2e9o5] The resulting framework describes digital twins as virtual models of bioprocesses, equipment, or entire facilities that are dynamically linked to real‑time data and can be used across “the drug product lifecycle.” [v2e9o5] By tailoring the digital‑twin concept to the realities of biomanufacturing—batch processes, complex biologics, regulatory constraints—the initiative helps companies move beyond pilot projects toward standardized, scalable digital infrastructures. [v2e9o5] [sacri9]
This case illustrates how biomanufacturing is no longer limited to wet‑lab operations but encompasses sophisticated data and modeling layers; the manufacturing system itself is treated as a cyber‑physical object that can be simulated, optimized, and validated virtually before changes are implemented on the shop floor. [v2e9o5] [sacri9] It also shows that definitional work by specialized consortia, not large incumbents alone, is shaping the practice of advanced biomanufacturing.

2. Sustainable Bio‑manufacturing of Polyhydroxyalkanoates (PHAs)

At the Global Center for Sustainable Bioproducts, researchers pursue “bio‑manufacturing” of polyhydroxyalkanoates (PHAs), a family of biodegradable polymers produced by microorganisms, as an alternative to petrochemical plastics. [3ijjtn] Their stated goal is “to accelerate the design-build-test-learn (DBTL) cycle of PHA biosynthesis in conjunction with the upstream supply chain of sustainable feedstocks,” emphasizing both strain engineering and integration with biomass sources. [3ijjtn] This work involves designing microbial production strains, optimizing bioreactor conditions, and developing downstream recovery steps suitable for scaling to industrial volumes—core elements of biomanufacturing. [3ijjtn]
The case highlights biomanufacturing as a sustainability‑driven industrial practice, where the key innovation lies not only in the biology but also in linking that biology to feedstock logistics and manufacturing economics. [3ijjtn] [lpky89] It also underscores how academic centers and smaller research consortia are pioneering methodologies (e.g., DBTL cycles for materials bioproducts) that larger industrial adopters can later scale.

3. Biomanufacturing in European Industrial Strategy and Regulation

Recognizing the strategic importance of bio‑based production, EuropaBio established its Biomanufacturing Platform with the mission “to represent biomanufacturing at the highest policy levels in Europe” and to ensure it is embedded in the EU Industrial Strategy and in Europe’s “twin, green and digital transitions.” [8xlze4] In parallel, chemical industry association Cefic issued a position paper on “biotechnology and biomanufacturing” calling for “uniform definitions for biotechnology and biomanufacturing,” policy coherence in the proposed Biotech Act, and tools such as “regulatory sandboxes” and increased funding to support industrialization. [iw6fgp]
This policy‑oriented case shows how biomanufacturing has become a category of economic and regulatory planning, not just a technical term. [8xlze4] [iw6fgp] [lpky89] By arguing for tailored regulatory frameworks and investment mechanisms, these groups implicitly define biomanufacturing as a distinct industrial domain with specific needs (e.g., GMO regulations, skills development, data infrastructures) and as a lever for resilience, growth, and decarbonization in European industry. [8xlze4] [iw6fgp]

Sources